Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-Dara SC vs Rd in Frail Newly Diagnosed Multiple Myeloma
NCT03993912Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2019
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by CHU de Lille. Primary endpoint: Progression-Free Survival up to 84 months. Started Oct 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03993912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993912.